Alle verbonden artikelen

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Jaar : 2012
Journal : Lancet
Volume : 379(9816)
Pagina's : 633-40

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

Auteurs : Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M
Jaar : 2012
Journal : Breast Cancer Res. Treat.
Volume : 133(1)
Pagina's : 387-91

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Auteurs : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pagina's : vii155-66

Dissecting the heterogeneity of triple-negative breast cancer.

Auteurs : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pagina's : 1879-87

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Auteurs : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Jaar : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pagina's : 209

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Auteurs : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Jaar : 2012
Journal : Oncogene
Volume : 31(31)
Pagina's : 3569-83

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Auteurs : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pagina's : 612-22

Technological innovation and healthcare professionals' workloads: an ambiguous relationship.

Auteurs : de Pires DE, Bertoncini JH, Trindade Lde L, Matos E, de Azambuja E, Borges AM
Jaar : 2012
Journal : Rev Gaucha Enferm
Volume : 33(1)
Pagina's : 157-68

Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?

Auteurs : Gombos A, Metzger-Filho O, Dal Lago L, Awada A
Jaar : 2012
Journal : Invest New Drugs
Volume : 30(6)
Pagina's : 2433-42

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Auteurs : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Jaar : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pagina's : 465-74

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Auteurs : Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pagina's : vi5-vi6

Second primary cancers in head and neck cancer patients: a challenging entity.

Auteurs : de Castro G, Awada A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 203-4

Thérapies biologiques ciblées et cancer thyroïdien récidivant : enfin un standard thérapeutique ?

Auteurs : Lalami Y
Jaar : 2012
Journal : Onco-Hémato
Volume : 6(5)
Pagina's : 45-51

Percutaneous endoscopic jejunostomy in patients with gastroparesis following lung transplantation: feasibility and clinical outcome.

Auteurs : Toussaint E, Van Gossum A, Ballarin A, Le Moine O, Estenne M, Knoop C, Devière J, Arvanitakis M
Jaar : 2012
Journal : Endoscopy
Volume : 44(8)
Pagina's : 772-5

Clinical development of new formulations of cytotoxics in solid tumors.

Auteurs : Azim HA, Awada A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 325-31

Význam biomarkerù v klinické onkologii

Auteurs : Klastersky J
Jaar : 2012
Journal : lekarsky Sbornik
Volume : sup1
Pagina's : 14-17

Esophageal self-expanding metallic stent (SEMS) migration: it's a topsy-turvy world.

Auteurs : Toussaint E, Zalcman M, Devière J, Le Moine O, Arvanitakis M
Jaar : 2012
Journal : Endoscopy
Volume : 44 Suppl 2
Pagina's : E352-3

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Auteurs : Awada A, Vandone AM, Aftimos P
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 297-304

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

Auteurs : Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, de Azambuja E, Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(4)
Pagina's : 853-859

Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer - Authors' reply.

Auteurs : Baselga J, de Azambuja E, Bradbury I, Gelber R
Jaar : 2012
Journal : Lancet
Volume : 379 (9833)
Pagina's : 2238